Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Asahi Pharma Co. Ltd.’s portfolio is identified in Biotechnology & Pharmaceuticals and has 1 pending office action. The profile lists 1 distinct examiner and 1 distinct art unit. VALLE, ERNESTO is the busiest examiner, with 1 pending matter. Examination activity is therefore concentrated in one recorded examiner and one assigned art-unit setting.
The prosecution team can focus its review on the pending action, the examiner’s stated concerns, and the application’s support for any proposed amendments. A response should distinguish the claimed pharmaceutical subject matter from the cited art without introducing unnecessary claim limitations. The single recorded examination path also supports maintaining one coherent position on claim construction and written-description support throughout the next filing.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044270 | COMPOUND FOR USE IN THE TREATMENT OF DRY MOUTH | VALLE, ERNESTO | 28d |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18044270 | COMPOUND FOR USE IN THE TREATMENT OF DRY MOUTH | VALLE, ERNESTO | 1623 | §103 | Non-Final OA | 28d | Pending | Mar 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAsahi Pharma Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ernesto Valle has the most, with 1 of Asahi Pharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
